# Neonc Technologies Holdings, Inc.: financial statements, quarterly

NTHI · Nasdaq · CIK 1979414 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nthi.md) · [Financials](/companies/nthi/financials.md) · [Filings](/companies/nthi/filings.md) · [Insiders](/companies/nthi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nthi/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001829126-25-003527.md) | [0.0](/filings/0001829126-25-006431.md) | [0.0 d](/filings/0001829126-25-009210.md) | [0.0 d](/filings/0001829126-26-002860.md) | [0.0](/filings/0001829126-26-005358.md) | [0.0 d](/filings/0001829126-26-008512.md) | [0.0 d](/filings/0001829126-25-009210.md) | [0.0 d](/filings/0001829126-26-002860.md) | not reported | [0.0](/filings/0001829126-26-008512.md) |
| Research and development | $m | [0.6](/filings/0001829126-25-003527.md) | [0.4](/filings/0001829126-25-006431.md) | [1.0](/filings/0001829126-25-009210.md) | [1.1 d](/filings/0001829126-26-002860.md) | [1.0](/filings/0001829126-26-005358.md) | [0.7](/filings/0001829126-26-008512.md) | [0.7](/filings/0001829126-25-009210.md) | [1.2 d](/filings/0001829126-26-002860.md) | [1.3](/filings/0001829126-26-005358.md) | [2.6](/filings/0001829126-26-008512.md) |
| Selling, general and administrative | $m | [0.1](/filings/0001829126-25-003527.md) | not reported | not reported | not reported | [0.1](/filings/0001829126-25-003527.md) | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(1.6)](/filings/0001829126-25-003527.md) | [(1.3)](/filings/0001829126-25-006431.md) | [(2.2)](/filings/0001829126-25-009210.md) | [(2.1) d](/filings/0001829126-26-002860.md) | [(31.9)](/filings/0001829126-26-005358.md) | [(5.7)](/filings/0001829126-26-008512.md) | [(6.9)](/filings/0001829126-25-009210.md) | [(13.7) d](/filings/0001829126-26-002860.md) | [(7.1)](/filings/0001829126-26-005358.md) | [(14.1)](/filings/0001829126-26-008512.md) |
| Interest expense | $m | [1.4](/filings/0001829126-25-003527.md) | [1.2](/filings/0001829126-25-006431.md) | [0.0 d](/filings/0001829126-25-009210.md) | [(0.0) d](/filings/0001829126-26-002860.md) | [0.3](/filings/0001829126-26-005358.md) | [0.0](/filings/0001829126-26-008512.md) | [0.9](/filings/0001829126-25-009210.md) | [1.3 d](/filings/0001829126-26-002860.md) | [1.0](/filings/0001829126-26-005358.md) | [0.2](/filings/0001829126-26-008512.md) |
| Net income | $m | [(2.9)](/filings/0001829126-25-003527.md) | [(4.5)](/filings/0001829126-25-006431.md) | [(2.2)](/filings/0001829126-25-009210.md) | [(2.3) d](/filings/0001829126-26-002860.md) | [(32.3)](/filings/0001829126-26-005358.md) | [(5.7)](/filings/0001829126-26-008512.md) | [(8.6)](/filings/0001829126-25-009210.md) | [(15.5) d](/filings/0001829126-26-002860.md) | [(8.8)](/filings/0001829126-26-005358.md) | [(14.2)](/filings/0001829126-26-008512.md) |
| Diluted EPS | $ per share | [(0.18)](/filings/0001829126-25-003527.md) | [(0.27)](/filings/0001829126-25-006431.md) | [(0.12)](/filings/0001829126-25-009210.md) | not reported | [(1.78)](/filings/0001829126-26-005358.md) | [(0.30)](/filings/0001829126-26-008512.md) | [(0.45)](/filings/0001829126-25-009210.md) | not reported | [(0.38)](/filings/0001829126-26-005358.md) | [(0.58)](/filings/0001829126-26-008512.md) |
| Basic EPS | $ per share | [(0.18)](/filings/0001829126-25-003527.md) | [(0.27)](/filings/0001829126-25-006431.md) | [(0.12)](/filings/0001829126-25-009210.md) | not reported | [(1.78)](/filings/0001829126-26-005358.md) | [(0.30)](/filings/0001829126-26-008512.md) | [(0.45)](/filings/0001829126-25-009210.md) | not reported | [(0.38)](/filings/0001829126-26-005358.md) | [(0.58)](/filings/0001829126-26-008512.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | [0.1](/filings/0001829126-26-002860.md) | [5.4](/filings/0001829126-25-003527.md) | [0.1](/filings/0001829126-25-006431.md) | [1.5](/filings/0001829126-25-009210.md) | [0.1](/filings/0001829126-26-008512.md) | [0.1](/filings/0001829126-26-005358.md) | [2.0](/filings/0001829126-26-008512.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | [2.2](/filings/0001829126-26-002860.md) | [7.4](/filings/0001829126-25-003527.md) | [1.7](/filings/0001829126-25-006431.md) | [3.0](/filings/0001829126-25-009210.md) | [1.4](/filings/0001829126-26-008512.md) | [2.1](/filings/0001829126-26-005358.md) | [4.2](/filings/0001829126-26-008512.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | [3.4](/filings/0001829126-26-002860.md) | [8.4](/filings/0001829126-25-003527.md) | [3.0](/filings/0001829126-25-006431.md) | [4.1](/filings/0001829126-25-009210.md) | [2.8](/filings/0001829126-26-008512.md) | [3.3](/filings/0001829126-26-005358.md) | [5.2](/filings/0001829126-26-008512.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | [8.9](/filings/0001829126-26-002860.md) | [18.1](/filings/0001829126-25-003527.md) | [14.5](/filings/0001829126-25-006431.md) | [15.6](/filings/0001829126-25-009210.md) | [20.0](/filings/0001829126-26-008512.md) | [16.3](/filings/0001829126-26-005358.md) | [23.5](/filings/0001829126-26-008512.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | [8.9](/filings/0001829126-26-002860.md) | not reported | [14.8](/filings/0001829126-25-006431.md) | [15.9](/filings/0001829126-25-009210.md) | [20.3](/filings/0001829126-26-008512.md) | [16.6](/filings/0001829126-26-005358.md) | [23.8](/filings/0001829126-26-008512.md) |
| Shareholders' equity | $m | [(14.0)](/filings/0001829126-26-002860.md) | [(16.9)](/filings/0001829126-25-009210.md) | [(6.2)](/filings/0001829126-25-009210.md) | [(5.3)](/filings/0001829126-25-009210.md) | [(5.5)](/filings/0001829126-26-008512.md) | [(9.6)](/filings/0001829126-26-008512.md) | [(11.8)](/filings/0001829126-26-008512.md) | [(11.8)](/filings/0001829126-25-009210.md) | [(17.5)](/filings/0001829126-26-008512.md) | [(13.2)](/filings/0001829126-26-008512.md) | [(18.5)](/filings/0001829126-26-008512.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [146](/filings/0001829126-25-003527.md) | [(318) d](/filings/0001829126-25-006431.md) | [(3,087) d](/filings/0001829126-25-009210.md) | [(954) d](/filings/0001829126-26-002860.md) | [(5,650)](/filings/0001829126-26-005358.md) | [(5,314) d](/filings/0001829126-26-008512.md) | [(5,809) d](/filings/0001829126-25-009210.md) | [(3,591) d](/filings/0001829126-26-002860.md) | [(6,992)](/filings/0001829126-26-005358.md) | [(4,765) d](/filings/0001829126-26-008512.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [16.6](/filings/0001829126-25-003527.md) | [16.6](/filings/0001829126-25-006431.md) | [17.9](/filings/0001829126-25-009210.md) | [18.1](/filings/0001829126-26-005358.md) | [19.0](/filings/0001829126-26-008512.md) | [19.2](/filings/0001829126-25-009210.md) | [23.3](/filings/0001829126-26-005358.md) | [24.7](/filings/0001829126-26-008512.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 25,936,365 at 2026-08-10, from the cover of the [10-Q filed 2026-08-10](/filings/0001829126-26-008512.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.